Please use a PC Browser to access Register-Tadawul
Get It
On December 22, 2023, Alaunos Therapeutics Entered Into Separation And Release Agreement With CEO Kevin Boyle In Connection With Boyle's Termination - Filing
Alaunos Therapeutics, Inc. - Common Stock TCRT | 5.00 | -1.19% |
The Company and Boyle also entered into a consulting agreement, effective January 1, 2024, pursuant to which Boyle will continue providing strategic and advisory services to the company. The Consulting Agreement will continue for a period of six months.